



**American Society for Experimental NeuroTherapeutics**

342 North Main Street ♦ West Hartford, CT 06117

Phone: (860) 586-7570 ♦ Fax: (860) 586-7550

E-mail: [info@asent.org](mailto:info@asent.org) ♦ Web Site: <http://www.asent.org>

**ABSTRACT SUBMISSION GUIDELINES**

**SUBMISSION:** Abstracts must be submitted electronically via the ASENT website, [www.asent.org](http://www.asent.org). Submission deadline is Monday, January 16, 2012.

**LENGTH:** No more than 3,200 characters for body text

The following guidelines address key factors that the ASENT 14<sup>th</sup> Annual Meeting Program Committee considers when reviewing abstracts. Attention to these details will assist the Committee in making their decision.

1. The abstract should describe original research broadly relevant to the goal of ASENT, which is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.
2. Character limit: 3,200 characters for body text, not including header (authors and institution/addresses), table or images. The abstract should include the following headings: background, methods, results and conclusions.
3. Title should be in upper and lower case (not all capital letters). Do not use abbreviations in the title unless they are universally understood in the field (e.g., EEG, MRI, PET scan).
4. Author names should appear below the title, followed by affiliations with addresses. Superscript numbers should be used after the author's names in cases where there are multiple affiliations.
5. Figures, images and table are acceptable. A maximum of two such display items may be used.
6. Use standard abbreviations sparingly. Acceptable abbreviations are given in the style guide of *Neurotherapeutics*. Spell out abbreviations when first used. Sufficiently detailed names of chemical compounds should be given so that they can be uniquely identified. Accepted generic names for drugs should be used, although brand names may be used once in parentheses after the first mention.
7. The results and an interpretation of the significance of the work should be given. It is not acceptable to state "results will be discussed."
8. Literature citations are ordinarily not provided in abstracts. In cases where citations are required, these should be included in the body of the abstract and formatted according to the *Neurotherapeutics* style.

9. Work presented in abstracts should conform to accepted ethical standards for human or animal research.
10. The financial sponsor(s) of the study should be listed at the end of all abstracts. Sources of funding should be acknowledged and any relevant competing interests should be disclosed.
11. Original abstracts will ordinarily be published in the ASENT journal, *Neurotherapeutics*, unless the submitting author requests that they not be published. Posters that have been previously presented at another scientific meeting may be presented at the ASENT Annual Meeting, but the abstracts will not be published in *Neurotherapeutics*.
12. Receipt of abstracts will be acknowledged via e-mail to authors upon successful submission.
13. Notification for those abstracts selected for presentation will be sent by January 23, 2012. A joint Information Exchange/Poster Session will take place on Wednesday, February 22, 2012, with ISCTM.
14. Anyone who submits, and has accepted, a new and/or previously unpublished poster will receive a complimentary registration to the 14<sup>th</sup> Annual Meeting. All abstract presenters bringing previously published posters will be required to pay a registration fee for the meeting.

If you are unable to submit an abstract electronically and wish to discuss alternative options, contact the ASENT office at (860) 586-7570 ext. 205.